TG Therapeutics (TGTX) Competitors $37.35 -1.99 (-5.06%) Closing price 04:00 PM EasternExtended Trading$37.05 -0.30 (-0.80%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. BNTX, TEVA, SMMT, ITCI, GMAB, RDY, MRNA, VTRS, ASND, and QGENShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. BioNTech Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Ascendis Pharma A/S Qiagen TG Therapeutics (NASDAQ:TGTX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Is TGTX or BNTX more profitable? TG Therapeutics has a net margin of -5.42% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% BioNTech -15.16%-2.35%-2.05% Do analysts rate TGTX or BNTX? TG Therapeutics presently has a consensus price target of $40.67, suggesting a potential upside of 7.18%. BioNTech has a consensus price target of $143.44, suggesting a potential upside of 63.65%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83BioNTech 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has better earnings and valuation, TGTX or BNTX? BioNTech has higher revenue and earnings than TG Therapeutics. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329.00M18.11$12.67M$0.14271.03BioNTech$2.75B7.65$1.01B-$3.00-29.22 Does the MarketBeat Community prefer TGTX or BNTX? TG Therapeutics received 514 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 46.93% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% BioNTechOutperform Votes14546.93% Underperform Votes16453.07% Do insiders and institutionals hold more shares of TGTX or BNTX? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.5% of TG Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, TGTX or BNTX? TG Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Does the media refer more to TGTX or BNTX? In the previous week, BioNTech had 9 more articles in the media than TG Therapeutics. MarketBeat recorded 25 mentions for BioNTech and 16 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.16 beat BioNTech's score of 0.35 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 8 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioNTech beats TG Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.87B$6.32B$5.24B$7.07BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-373.466.7221.2017.47Price / Sales17.83186.91356.3585.24Price / Cash353.9065.6738.1634.64Price / Book35.245.576.233.79Net Income$12.67M$141.67M$3.20B$247.10M7 Day Performance-6.30%-11.44%-8.32%-7.32%1 Month Performance4.86%-14.59%-3.36%-10.20%1 Year Performance158.30%-18.30%2.72%-7.41% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics2.7954 of 5 stars$37.35-5.1%$40.67+8.9%+171.9%$5.87B$329.00M-373.46290Positive NewsGap DownBNTXBioNTech2.6587 of 5 stars$91.06-4.1%$143.73+57.8%+1.4%$21.85B$2.75B-43.363,080Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeTEVATeva Pharmaceutical Industries2.2157 of 5 stars$15.39+2.0%$23.43+52.3%+5.1%$17.44B$16.54B-10.6136,800Analyst UpgradeShort Interest ↑Analyst RevisionGap DownSMMTSummit Therapeutics2.8063 of 5 stars$19.29-5.1%$35.44+83.7%+378.7%$14.23B$700,000.00-68.89110Gap DownITCIIntra-Cellular Therapies3.4634 of 5 stars$131.92+0.1%$106.08-19.6%N/A$14.05B$680.50M-151.63560Analyst ForecastNews CoveragePositive NewsGMABGenmab A/S3.7504 of 5 stars$19.58-1.6%$41.33+111.1%-34.3%$12.96B$21.53B11.251,660Analyst DowngradeGap DownRDYDr. Reddy's Laboratories3.2407 of 5 stars$13.19-0.1%$17.00+28.9%-9.5%$11.01B$311.31B21.0024,800Positive NewsGap DownMRNAModerna4.221 of 5 stars$28.35-8.9%$59.00+108.1%-74.6%$10.96B$3.20B-3.053,900Gap DownVTRSViatris2.5312 of 5 stars$8.71+0.3%$10.50+20.6%-32.1%$10.40B$14.74B-11.7737,000ASNDAscendis Pharma A/S2.9378 of 5 stars$155.86+0.8%$204.64+31.3%+0.4%$9.46B$363.64M-21.951,017Positive NewsGap DownQGENQiagen3.9587 of 5 stars$40.17+0.8%$47.71+18.8%-0.9%$8.91B$1.98B111.866,030Analyst Downgrade Remove Ads Related Companies and Tools Related Companies BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
